Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition  by Hasson, Tal et al.
Journal of Neuroimmunology 290 (2016) 84–95
Contents lists available at ScienceDirect
Journal of Neuroimmunology
j ourna l homepage: www.e lsev ie r .com/ locate / jneuro imFunctional effects of the antigen glatiramer acetate are complex and
tightly associated with its compositionTal Hasson b,1, Sarah Kolitz a,⁎,1, Fadi Towﬁc a, Daphna Laifenfeld b, Shlomo Bakshi b, Olga Beriozkin b,
Maya Shacham-Abramson b, Bracha Timan b, Kevin D. Fowler a, Tal Birnberg b, Attila Konya c, Arthur Komlosh b,
David Ladkani b, Michael R. Hayden b, Benjamin Zeskind a,1, Iris Grossman b,⁎⁎,1
a Immuneering Corporation, Cambridge, MA, USA
b Teva Pharmaceutical Industries, Petach Tikva, Israel
c Teva Pharmaceutical Works Ltd., Hungary⁎ Correspondence to: S. Kolitz, Immuneering Corporat
Cambridge, MA 02142, USA.
⁎⁎ Correspondence to: I. Grossman, Teva Pharmaceut
Petach Tikva 49131, Israel.
E-mail addresses: skolitz@immuneering.com (S. Kolitz
(I. Grossman).
1 These authors contributed equally.
http://dx.doi.org/10.1016/j.jneuroim.2015.11.020
0165-5728/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 30 September 2015
Received in revised form 16 November 2015






Therapeutic equivalenceGlatiramer acetate (Copaxone®; GA) is a non-biological complex drug for multiple sclerosis. GA modulated
thousands of genes in genome-wide expression studies conducted in THP-1 cells and mouse splenocytes.
Comparing GA with differently-manufactured glatiramoid Polimunol (Synthon) in mice yielded hundreds
of differentially expressed probesets, including biologically-relevant genes (e.g. Il18, adj p b 9e−6) and
pathways. In human monocytes, 700+ probesets differed between Polimunol and GA, enriching for
130+ pathways including response to lipopolysaccharide (adj. p b 0.006). Key differences were conﬁrmed
by qRT-PCR (splenocytes) or proteomics (THP-1). These studies demonstrate the complexity of GA's mech-
anisms of action, and may help inform therapeutic equivalence assessment.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glatiramer acetate (GA; Copaxone®) has been safely used to treat
multiple sclerosis (MS) patients for almost twodecades. Compositionally,
it is a heterogeneous colloidalmixture of polymericmolecules, each up to
300 amino-acids long. Up to 1029 variants are present in themixture, sub-
sets of which exist at subpicogram quantities and thus remain unidenti-
ﬁable with current state-of-the-art methodologies. Upon subcutaneous
injection, GA is immediately hydrolyzed at the site of the injection,
resulting in an undetectable systemic pharmacokinetic proﬁle. Further-
more, the therapeutic properties of GA have yet to be correlated with
any type of validated pharmacodynamic biomarker. Indeed, GA's active
moiety(ies), ie, the speciﬁc amino acid sequences (acting effectively as
immunological “epitopes”, or antigenic motifs that uniquely activate cer-
tain aspects of the immune system) responsible for its clinical efﬁcacy,
have yet to be identiﬁed. Harnessing high resolution, comprehensive,
andunbiasedmethods is essential to furthering the scientiﬁc understand-
ing of the complex mode of action of GA.ion, One Broadway, 14th Floor,
ical Industries Ltd., 5 Basel St,
), Iris.Grossman@teva.co.il
. This is an open access article underThe clinical effects of GA are believed to result from its functioning as
an antigen modulating the immune system. GA was designed to mimic
the autoantigen myelin basic protein (MBP), which is attacked by the
immune system in multiple sclerosis. After degradation at the injection
site, GA is thought to bindMHCClass IImolecules on antigen-presenting
cells (APCs), which interact with naïve T-cells, generating GA-speciﬁc
T-cells and shifting their phenotype from pro-inﬂammatory helper-T
types 1 and 17 (Th1/Th17) to anti-inﬂammatory regulatory T cells
(Tregs) and helper-T type 2 (Th2) cells (Duda et al., 2000; Neuhaus
et al., 2000; Arnon and Aharoni, 2004). GA-speciﬁc T-cells are able to
migrate through the blood–brain barrier (BBB) and some of them
cross-react with the similarly-structuredMBP or other myelin associat-
ed antigens inducing local secretion of anti-inﬂammatory cytokines at
the site of the lesions, shifting the balance from a pro-inﬂammatory
(Th1/Th17) to anti-inﬂammatory (Th2/Treg) phenotype (Neuhaus
et al., 2000; Arnon and Aharoni, 2004; Aharoni et al., 2010). GA also
induces type-II monocytes, which direct differentiation of Th2 and
protective Tregs (Kim et al., 2004; Weber et al., 2007), an effect
that is independent of antigen speciﬁcity; thus cross-reactivity of T
cells with myelin antigen is not required for therapeutic beneﬁt
(Weber et al., 2007). In addition, GA promotes production of neuro-
trophic factors such as BDNF by T cells (Arnon and Aharoni, 2004),
and induces B-cell activation, which appears necessary for GA
response in animal models (Jackson et al., 2014). Data from GA-
treated MS patients indicate that GA also modulates CD8+ T cellthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Numbers of differentially expressed probesets in each model system.
a) Mouse splenocyte data:
Immunization Treatment comparison Total Up-regulated Up, FC ≥ 2 # pathways Down-regulated Down, FC ≤ −2 # pathways
Copaxone Copaxone-mannitol 16,647 8342 411 76 8305 485 56
Immunization Treatment comparison Total Up-regulated Up, FC ≥ 1.2 # pathways Down-regulated Down, FC ≤ −1.2 # pathways
Copaxone (Polimunol-mannitol)-(Copaxone-mannitol) 223 208 73 22 15 6 0
Polimunol (Polimunol-mannitol)-(Copaxone-mannitol) 431 301 77 10 130 22 0
Corresponding
to treatment
(Polimunol-mannitol)Pol-(Copaxone-mannitol)Cop 462 362 206 25 100 30 3
b) THP-1 data:
Treatment comparison Total Up-regulated Up, FC ≥ 1.3 # pathways Down-regulated Down, FC ≤ −1.3 # pathways
Pre-ﬁltering Copaxone-mannitol 12,115 5296 456 180 6819 183 6
Post-ﬁltering Copaxone-mannitol 12,001 5227 456 180 6774 183 6
Treatment comparison Total Up-regulated Up, FC ≥ 1.1 # pathways Down-regulated Down, FC ≤ −1.1 # pathways
Pre-ﬁltering (Polimunol-mannitol)-(Copaxone-mannitol) 807 518 241 177 289 80 0
Post-ﬁltering (Polimunol-mannitol)-(Copaxone-mannitol) 779 494 218 137 285 78 0
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involved in GA action.
The complexity of GA's mechanism of action (MoA) cannot be fully
captured by any one in vitro or in vivo system. Genome-wide expres-
sion proﬁling of splenocytes extracted from GA-treated mice serves to
capture elements of the biological impact in T cells, given the observed
physicochemical differences between GA and other glatiramoids
(Weinstein et al., 2015). This model system has demonstrated utility
as a means to model GA's interaction with lymphocytes (Bakshi et al.,
2013; Towﬁc et al., 2014); and similar studies in a human monocyte
cell line have been used to study GA's impact on APCs (Kolitz et al.,
2015). Together, these studies represent all three key elements required
for GA's activation of “the immunological triad” — including lympho-
cytes, immunogenic epitopes, and APCs (Jackson et al., 2014;
Sellebjerg et al., 2013), while also accounting for some of the factors
that further modulate therapeutic response in vivo. Utilizing learnings
from previous studies of GA in these cell types, a reciprocal-control ex-
perimental design was applied in order to further elucidate GA's MoA
and to assess the degree towhich thesemechanisms are sensitive to dif-
ferences in composition and manufacturing of the therapeutic antigen.
Namely, mouse splenocytes were utilized to model three likely clinical
scenarios in a single experiment. The ﬁrst scenario models a patient
treated initially with GA and then switched to a follow-on glatiramoid
(FOGA), which is modeled by immunizingmicewith GA and then com-
paring the gene expression proﬁles when extracted splenocytes are
activated ex vivo with either GA or FOGA. The second scenario is one
in which a patient is treated initially with a FOGA and then switched
to GA, which ismodeled by immunizingmicewith FOGA and then com-
paring the gene expression proﬁles when extracted splenocytes are ac-
tivated ex vivo with either GA or FOGA. The third scenario models a
setting in which a patient is treated purely with either GA or FOGA,
such that comparison of the gene expression proﬁles derived from the
activated splenocytes in each experiment may reﬂect long-term
treatment-induced functional differences. This experimental design
was combined with mRNA and proteomic studies conducted with the
same glatiramoids in a humanmonocyte cell line, previously published
as consistent with human primary monocyte studies in glatiramoids
(Kolitz et al., 2015). Taken together, these orthogonal experimental
models, biomarker technologies, and functional analyses provide im-
portant insights into GA's mode of action and differences with FOGAs.
The analysis of multiple lots of GA was conducted in parallel to
Synthon's FOGA (Polimunol®), marketed in Argentina as a purported
clinical equivalent to GA (as of May 2014). Polimunol is believed to be
the same Synthon FOGA (entitled “GTR”) used in the only bridgingclinical trial conducted to date with the objective of demonstrating sur-
rogate equivalence to GA in terms of MRI measurements (GATE study,
NCTNumber NCT01489254). The authors report that for T1-GdE lesions
during months 7–9 the “GTR/GA ratio was within the pre-deﬁned
margins”. However, according to results reported from the placebo-
controlled phase of the study (Cohen et al., 2014), clinical equivalence
in terms of annualized relapse rate (ARR), as well as correlation be-
tweenMRI-lesion predictors andARR reductions, have not beenmet, in-
dicating lack of sameness in therapeutic effect. It is for these reasons
that studies comparing Synthon's FOGA to GA using high-resolution
physicochemical tests, as well as genome-wide expression studies in
immunologically relevant model systems, are of keen interest to the
scientiﬁc and medical community worldwide, considering that no
traditional therapeutic equivalence methods have been shown to be
clinically validated for this class of compounds. Thus, careful investiga-
tion and establishment of novel preclinical and clinical standards are
needed in evaluating therapeutic equivalence between FOGAs and GA.
2. Materials and methods
2.1. Reciprocal mouse splenocyte study: experimental design and methods
2.1.1. Mice
All experimental procedures conformed to accepted ethical
standards for use of animals in research and were in accordance with
Committee for the Care and Use of Experimental Animals guidelines
and approved by the Teva Institutional Animal Care andUse Committee.
8- to 12-week-old female (Balb/c X SJL) F1 mice (Janvier, France) were
purchased, and kept at 21 ± 3 °C with relative humidity 30%–70%, and
light/dark cycle 12:12 h. Animals weremaintained on a standard rodent
pellet diet and sterile ﬁltered tap water available ad libitum.
2.1.2. Immunization of mice and preparation of ex vivo spleen cell cultures
To stimulate induction of GA and FOGA-reactive T cells, twelvemice
in each treatment group were injected subcutaneously with 100 μL of a
2.5mg/mL solution of either Copaxone (GA drug product, Teva Pharma-
ceutical Industries, Petach Tikva, Israel) or Polimunol (FOGA drug
product, Synthon, Nijmegen, Netherlands) in phosphate-buffered saline
(250 μg GA per mouse). Mice were housed for 3 days after immuniza-
tion, then sacriﬁced. Spleens were aseptically removed and placed on
ice in RPMI 1640. A single cell suspension was prepared. After red
blood cell lysis, splenocytes from the same immunization group were
pulled and resuspended to a ﬁnal concentration of 10 × 106 cells/mL
in deﬁned cell culture medium (DCCM1) (Biological Industries, Beit
86 T. Hasson et al. / Journal of Neuroimmunology 290 (2016) 84–95Haemek, Israel) (96.7% v/v) enriched with L-glutamine 2 mM (1% v/v),
MEM Non-Essential Amino Acids 2 mM (1% v/v), sodium pyruvate
1 mM (1% v/v), antibiotic/antimycotic solution (0.2% v/v) and 2-
mercaptoethanol 50 mM (0.1% v/v).
2.1.3. In vitro cell activation
Splenocytes were treated with activator samples diluted in medium
(125 μL per well of 80 μg/mL solutions, ﬁnal concentration in the well
after addition of cells: 40 μg/mL) of: (i) 3 different lots of GA drug prod-
uct manufactured by Teva, or (ii) one lot of FOGA (Polimunol). The acti-
vator samples or mannitol (the nonactive excipient in GA/FOGA drug
products, used as control in the experiment) in medium were added
to 96-well tissue-culture plates (three wells per sample). Splenocytes
(125 μL 10 × 106 cell/mL suspension) were added to the activator solu-
tions. Each activator sample was loaded in 2 different plates, 1 for cells
from mice immunized with GA and 1 for cells from mice immunized
with purported generic. Plates were incubated for 24 h at 37 °C in 5%
CO2 atmosphere. Cells were collected and centrifuged at 300 g for
5 min. Supernatants were aspirated and cell pellets resuspended in
RLT buffer (from RNeasy mini kit of Qiagen, Cat # 74106) for cell lysis.
Cell lysates were centrifuged and supernatants collected and frozen at
−70 °C. Samples were sent for further processing. RNA was extracted
and expression-proﬁled across the entire genome using the Affymetrix
Mouse Genome 430_2 chip (Expression Analysis |Quintiles, Durham
NC). Three lots of GA and 1 lot FOGA were comparatively tested in 6
biological replicates each, as dictated by power-analysis calculations
performed using the R statistical package ssize.fdr to determine the
number of samples needed to detect differentially-expressed genes
with a fold-change between treatments of as low as 1.3 with 80%
power. Two technical replicates were used, resulting in 12 replicates
per condition.
2.1.4. qRT-PCR conﬁrmation
Ten genes (Il10, Il4, Foxp3, Il18, Mmp8, Rsad2, Ddx58, Irf7, Mx1,
Iﬁ202b) were chosen for testing based on showing signiﬁcant modula-
tion in themicroarray observations as well as potential biological inter-
est. Experimental assistance was provided by EA/Quintiles. Expression
levels of the ten genes were measured using qRT-PCR with 18S rRNA
as reference transcript, and mannitol samples as calibrator. Relative
quantiﬁcation (RQ) values were computed as 2−ΔΔCt. Differences in
expression levels were evaluated for signiﬁcance using 2-sided t tests
with equal variance.
2.2. THP-1 microarray study experimental design and methods
Cells from a human monocyte cell line (THP-1) were stimulated
with either branded GA drug product, FOGA (Polimunol), or vehicle
control (mannitol) for 6 h based on prior observations of GA effects
in this model system (Kolitz et al., 2015). RNA was extracted and
expression-proﬁled in a blinded fashion across the entire genome,
using the Affymetrix Human Genome U133 Plus 2.0 chip, interrogating
a total of over 47,000 transcripts (Expression Analysis |Quintiles, Dur-
ham NC). Three lots of GA and 1 lot of FOGA were comparatively tested
in 6 biological replicates each. This entire experiment was performed
independently twice, using an identical study design, reagents and
compounds by the same technicians on 2 separate days; resulting in
12 biological replicates total per condition.
2.3. THP-1 proteomic study experimental design and methods
Cells from the same human monocyte cell line (THP-1) were incu-
bated with either branded GA, FOGA Polimunol, or vehicle control
(mannitol) for 24 h, expected to reﬂect translation of mRNA expression
patterns observed in the same study design at 6 h post stimulation.
Supernatants (1.0 mL of cell culture media) were collected and assayed
for the concentration of selected proteins using a custom Luminex assayto measure the concentrations of a panel of 42 chemokines and cyto-
kines (in pg/ml) using Bio-Plex Human Chemokine (Bio Rad kit) and
Luminex Performance Assay (R&D kit). Five biological replicates per
condition were used.
2.3.1. Data analysis for proteomic data
Data (concentrations in pg/mL)were comparedusing a 2-sided t test
with equal variance and corrected for multiple hypothesis testing using
Benjamini–Hochberg correction. To calculate the fold change between
the protein expression levels with FOGA and with GA, GA values were
averaged together and compared with the average value for Polimunol
(average Polimunol expression level/average GA expression level).
2.4. A priori power analysis
Using the R statistical package ssize.fdr, power calculations were
performed to determine the number of samples needed to detect
differentially-expressed genes with a fold-change between treatments
of as low as 1.3with 80% power. Based on the results of these power cal-
culations, the experiment was designed to include 6 biological repli-
cates of each condition. The order in which samples were processed
was randomized with respect to treatment and stimulation time to
avoid creating confounding batch effects.
2.5. Analysis methods for microarray studies
2.5.1. Outlier identiﬁcation
Outlier samples were identiﬁed using the R package ArrayQCMetrics
and excluded from further data processing steps. A sample was consid-
ered an outlier if it failed more than half of the included tests either be-
fore or after RMA normalization. For mouse splenocyte data, 6 samples
(3.8%) were determined to be outliers, and for THP-1 data, 2 samples
(2.4%) were determined to be outliers by these criteria. Data were
RMA normalized using the Affy R package.
2.5.2. Batch correction
Correction for batch variation was performed using ComBat
(Johnson et al., 2007), as implemented in the SVA R package (Leek
et al., 2013). Brieﬂy, ComBat is an empirical Bayesian approach using lo-
cation and scale metrics across several genes to adjust for batch effects
in datasets, even datasets containing small sample sizes. For mouse
splenocyte data, date of microarray experiment was used as batch,
and the combination of treatment and immunization was used as
covariate. For THP-1 data, date of experiment was utilized as batch
and treatment labels were added as covariates to the batch correction
to preserve relevant treatment effects. Principal Component Analysis
(a multivariate approach) showed that the main effect in the ﬁrst
principal component remained due to treatment effects after batch
correction.
2.5.3. Differential expression analysis
Differentially-expressed probesets were identiﬁed across conditions
using linear models for microarray data (LIMMA) (Smyth, 2004). Com-
parisons of GA and purported generic were corrected to compare each
treatment relative to mannitol control (e.g., [GA vs mannitol] was com-
pared via LIMMAwith [Polimunol vsmannitol]). Probesetswere ﬁltered
by MAS5 calls of presence on the chip (to be considered present, a
probeset was required to have on average a call of present or marginal
across samples).
For mouse splenocyte studies, probesets were mapped to genes
using the annotation available for the Mouse_430_2 chip from
Affymetrix. For the comparison of immunization and activation with
GA versus immunization and activation with FOGA, an additional
correction for run order, performed using LIMMA (Smyth, 2004), was
evaluated (Supplementary Table 2).
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probesets highly variable between THP-1 datasets, as follows: a
probeset was deemed highly variable if across three THP-1 studies to
date, that probeset was observed to be upregulated, downregulated,
and not modulated by GA across the three studies. This criterion result-
ed in ﬁltering out 216 probesets. Probesets weremapped to genes using
the annotation available for the U133 Plus 2.0 chip from Affymetrix.
Unless otherwise noted, FDR-adjusted p values reported for genes
represent the lowest FDR-adjusted p value for present probesets for
that gene.
2.5.4. Pathway enrichment analysis
Upregulated and downregulated probesets were analyzed separate-
ly for pathway enrichment, using DAVID (Huang et al., 2009). The back-
ground used was probesets with present calls on the chip. Results were
visualized using volcano plots, plotting− log adjusted p values versus
enrichment scores for the pathways. Fold-change (FC) cutoffs were
utilized to obtain lists of probesets of a size appropriate for the step
of pathway enrichment using DAVID. For comparisons between GA
and Polimunol, upregulated or downregulated probesets with FDR-
adjusted p values b 0.05 and fold changes with absolute value ≥ 1.2
(for mouse splenocyte study) or 1.1 (for THP-1 study) were used. For
comparisons between GA andmannitol, upregulated or downregulated
probesets with FDR-adjusted p values b 0.05 and FCwith absolute valueFig. 1. In splenocytes frommice immunized with GA, GA treatment increased expression of the
(a), and decreased expression of the gene for the pro-inﬂammatory cytokine IL-12a (b).greater than 2 (mouse splenocyte study) or 1.3 (THP-1 study) were
used. DAVID runs were conducted in December 2014 and January 2015.
3. Results
3.1. Reciprocal mouse splenocyte studies
3.1.1. GA mechanism of action
Analyzing splenocytes from mice immunized as well as activated
with GA, 16,647 probesets were signiﬁcantly modulated relative to
mannitol: 8342 (representing 5101 genes) increased in expression
level (throughout, termed upregulated) and 8305 (5208 genes) de-
creased in expression level (throughout, termeddownregulated). Filter-
ing by |FC| ≥ 2, 411 probesets (271 genes) were upregulated and 485
(355 genes) downregulated (Table 1).
As expected, GA treatment upregulated key anti-inﬂammatory cyto-
kine genes Il10 and Il4 (adj p b 2.3e−24 and 5.1e−35, respectively;
Fig. 1a), as well as markers of regulatory T cells, Foxp3 and Gpr83
(adj p b 3.4e−23 for Foxp3; Fig. 1a; adj p b 4.2e−33 and 9.0e−31 for
the 2 Gpr83 probesets). Complementarily, GA downregulated pro-
inﬂammatory cytokine genes such as Il12a (adj p b 8.3e−31; Fig. 1b).
After imposing a conservative fold change ﬁlter of |FC| ≥ 2, 411
probesets were upregulated by GA relative to mannitol (in GA-
immunized mice). These probesets enriched for 76 pathways, many ofgenes for anti-inﬂammatory cytokines IL-10 and IL-4 and regulatory T cell marker FOXP3
88 T. Hasson et al. / Journal of Neuroimmunology 290 (2016) 84–95which are immunologically relevant, and include relevant aspects of
GA's MoA such as the cytokine–cytokine receptor interaction pathway
identiﬁed also in the THP-1 data described below. Similarly, after ﬁlter-
ing by |FC| ≥ 2, 485 downregulated probesets were detected, enriching
for 56 pathways, a number of which are associated with modulation of
the immune system. Both the upregulated and downregulated path-
ways are depicted in Fig. 2, and the full list is provided in Supplementary
Table 1.
3.1.2. GA versus differently-manufactured FOGA Polimunol
First, the “switching”model was utilized to detect genomic modula-
tion associatedwith activation by a differentlymanufactured FOGA than
the immunization agent, GA. Thismodel is expected to emulate the clin-
ical situation of FOGA introduction in the market and forced-switching
of GA-treated patients to FOGA mid-treatment.
When splenocytes fromGA-immunizedmicewere activated ex vivo
with either FOGA or GA and compared to each other while controlling
for mannitol, 223 probesets were found to be differentially expressed
at FDR p b 0.05 (208 were upregulated, 15 were downregulated).
The top upregulated probesets by FOGA versus GA are reported in Sup-
plementary Table 3 and include many interferon-induced genes, as de-
tailed in the pathway enrichment section below. The 15 downregulated
probesets by FOGA versus GA are reported in Supplementary Table 4.
Next, the reciprocal experiment was carried out, conducting the
immunization with FOGA rather than GA. When splenocytes from
FOGA-immunized mice were activated with GA versus activation by
the same FOGA and controlling for mannitol, 431 probesets were differ-
entially expressed (adj p b 0.05; 301 upregulated, 130 downregulated).
The top upregulated probesets by FOGA versus GA are reported in
Supplementary Table 5. This list overlaps greatly (149 of 208 = 72%)
with probesets upregulated in the reciprocal comparison described
above (ie, same study design except immunization agent being GA
rather than FOGA). This consistency is highly statistically signiﬁcant
(p b 1e−10 by hypergeometric test) and includes many interferon-
induced genes. Similar observations for downregulated probesets by
FOGA versus GAwere obtained, and the top results are reported in Sup-
plementary Table 6.
The genes depicted as differentially modulated by FOGA compared
with GA are linked to clinically relevant functionality, speciﬁcally as
relates to treatment of multiple sclerosis. For instance, while Il18 andFig. 2. Pathways enriched among topprobesetsmodulated byGA relative tomannitol in splenoc
p value b 0.05.its receptor Il18r1were both signiﬁcantly downregulated by the 2 acti-
vation treatments, regardless of immunization agent (GA or FOGA), Il18
was downregulated signiﬁcantly less by FOGA than by GA (differential
expression adj p b 9e−6, FC = 1.20 under GA immunization, and adj
p b 2e−9, FC = 1.26 under FOGA immunization). Boxplots of Il18 ex-
pression appear in Fig. 3a.
After imposing a fold change ﬁlter of |FC| ≥ 1.2 and adjusting p value
for multiple testing, 73 probesets were found to be upregulated by
Polimunol relative to GA (mannitol-corrected, in GA-immunized
mice), enriching for 22 pathways, including immune response and de-
fense response. Several of these pathways may be relevant to GA's
MoA, since they were also enriched among probesets modulated by
GA relative to control (e.g., immune response, immune system process,
and defense response). Additional pathways, including response to
virus, RIG-I-like receptor signaling, and cytosolic DNA-sensing pathway,
are consistent with increased type I interferon signaling. A total of 6
downregulated probesets were detected, which do not enrich for any
known pathway. The upregulated pathways are depicted in Fig. 4a
and the full list of pathways in Supplementary Table 7.
The same analysis conducted in the reciprocal study design with
Polimunol-immunization (imposing ﬁlters of |FC| ≥ 1.2 and adjusted
p b 0.05), 77 probesets were upregulated signiﬁcantly by Polimunol
relative to GA (mannitol-corrected), and these probesets enriched for
10 pathways. The majority of the pathways overlapped with those
seen in the comparison for GA-immunized mice, and include pathways
relevant to GA's MoA such as immune response and immune system
process pathways. As with GA immunization, the response to virus
pathway was also enriched. Twenty-two downregulated probesets
were detected, which did not enrich for known pathways. The upregu-
lated pathways are depicted in Fig. 4b and provided in Supplementary
Table 8.
3.1.3. Comparison of single-agent immunization and activation sequence
with GA versus Polimunol
Gene expression proﬁles from splenocytes of GA-immunized mice
treated ex vivo with GA were compared with gene expression proﬁles
from splenocytes of Polimunol-immunized mice treated ex vivo with
Polimunol. 235 probesets were differentially expressed after imposing
a fold change ﬁlter of |FC| ≥ 1.2 and correction for multiple hypothesis
testing (FDR p value b 0.05); 206 of those were upregulated and 30ytes frommice immunizedwithGA. Thedashed line indicates signiﬁcance level of adjusted
Fig. 3. Il18 Expression is reduced to a greater extent by GA than Polimunol, regardless of which substance is utilized for the immunization, both in microarray data (a) and qRT-PCR con-
ﬁrmation (b).
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regulated probesets enriched signiﬁcantly for 25 pathways, including
response to virus (adj p b 3.6e−9) and RIG-I-like receptor signaling
(adj p b 0.004). These observations were consistent at the gene
and pathway level with the results of comparing Polimunol versus
GA treatment within GA-immunized mice (Supplementary Table 9,
Supplementary Fig. 1). In addition, the downregulated probesets
enriched signiﬁcantly for 3 pathways, including transmission of nerve
impulse (adj p b 0.04) (Supplementary Fig. 1, Supplementary Table 9).3.1.4. qRT-PCR conﬁrmation of key results
Ten genes (Il10, Il4, Foxp3, Il18, Mmp8, Rsad2, Ddx58, Irf7, Mx1,
and Iﬁ202b) were tested by qRT-PCR, to conﬁrm the microarray
ﬁndings for the above analyses. As expected (Supplementary Fig. 2a,
Supplementary Table 10) in follow-up of GA mode-of-action genes,
Il10, Il4, and Foxp3 were conﬁrmed as upregulated signiﬁcantly by GA
(p b 1.3e−13, p b 7.4e−18, and p b 4.8e−13, respectively).
As shown in Supplementary Table 10, the qRT-PCR results
also conﬁrmed microarray observations for differences between GA
and Polimunol. Each of the 7 genes tested due to differing expressionlevel by Polimunol versus GA treatment on the microarray also differed
signiﬁcantly in qRT-PCR, for each immunization condition.
Conﬁrming themicroarray results, Il18was signiﬁcantly upregulated
with Polimunol treatment relative to GA treatment, irrespective of im-
munization condition (either Polimunol or GA; p b 9.2e−4 and
p b 1.0e−5, respectively) (Fig. 3b), reﬂecting the observation that
Polimunol downregulated Il18 to a signiﬁcantly lesser extent than GA.
For each of the other 6 genes, GA treatment increased the expression
level relative to mannitol control, and Polimunol increased this expres-
sion level signiﬁcantly further.
Since several genes from the RIG-I pathway were signiﬁcantly up-
regulated by Polimunol compared with GA on the microarray, a few
were chosen for qRT-PCR testing, including Ddx58 (RIG-I) and Irf7. Con-
ﬁrmationwas obtained for both immunization conditions (Supplemen-
tary Fig. 2b). A number of other interferon-related genes were also
signiﬁcantly modulated by Polimunol relative to GA (Supplementary
Table 8), includingMx1 and Rsad2, which have been used or proposed
as markers of IFNβ response in multiple sclerosis (Hundeshagen et al.,
2012; Malhotra et al., 2011).Mmp8, a gene that has been implicated in
EAE (Folgueras et al., 2008), was also expressed more highly with
Polimunol versus GA treatment (Supplementary Fig. 2b).
Fig. 4. Pathways enriched among top probesets upregulated by Polimunol relative to GA,
in GA-immunizedmice (a) and Polimunol-immunizedmice (b). The dashed line indicates
signiﬁcance level of adjusted p value b 0.05. (c) Pathways of Type I interferon production
(adapted from (Trinchieri, 2010): ©2010 Trinchieri. Journal of Experimental Medicine.
207:2053-2063. http://dx.doi.org/10.1084/jem.20101664).
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3.2.1. GA mechanism of action
GA signiﬁcantly upregulated 5296 probesets (3164 genes), and
signiﬁcantly downregulated 6819 probesets (4586 genes), out of
N25,000 probesets called present on the chip. Consistent with previous
studies (e.g., Kolitz et al., 2015), the anti-inﬂammatory gene IL1RNwasstrongly upregulated by GA (all 3 IL1RN probesets that were called
present in the study: adj p values b 6.2e−21, 2.6e−17, 8.0e−14);
see Fig. 5a.
IL10was represented by a single probeset on the chip,whichwas not
called “present”, thus its modulation could not be determined. IL10RA,
representing the receptor necessary for IL10 signaling, was signiﬁcantly
upregulated (adj p b 1.7e−21), indicating this pathway upregulated by
GA, as expected.
Among the top probesets upregulated by GA, 180 pathways were
enriched (Fig. 5b, Supplementary Table 11). This includes immune re-
sponse, immune system process, cytokine–cytokine receptor interac-
tion, regulation of B cell activation, coagulation, positive regulation of
lymphocyte activation and proliferation, and positive regulation of
B-cell activation and proliferation. As an example of an enriched path-
way anticipated as relevant to GA MoA, cytokine–cytokine receptor
interaction, the individual genesmodulated byGA involved in this path-
way are depicted in Supplementary Fig. 3. Six pathways were enriched
among top probesets downregulated by GA, including developmental
processes, and cell–cell adhesion-related pathways. Many of the above
pathways were observed in a prior study (Kolitz et al., 2015).
3.2.1.1. Secreted proteinsmodulated byGA. To evaluate effects of GA at the
protein level, 42 secreted cytokines and chemokines were measured
from the supernatant of THP-1 cells stimulated for 24 hwith GA orman-
nitol control. Compared with mannitol control, GA signiﬁcantly
increased the levels of most of these proteins, including 34 out of 36
total proteins having sufﬁcient measurements for any testing. None of
the measured protein levels were decreased by GA.
3.2.2. Comparison of GA with Polimunol
Comparing Polimunol with GA, corrected for mannitol control
expression [ie, (Polimunol-mannitol)-(GA-mannitol)], resulted in 807
differentially-expressed probesets with FDR-adjusted p b 0.05: 518
upregulated and 289 downregulated.
After conservative ﬁltering of highly variable probesets (ie, the few
previously identiﬁed to have differing behavior between THP-1 studies,
which removed 3.5% of the 807 probesets), 779modulated probesets per-
sist: 494 upregulated probesets and 285 downregulated probesets (Sup-
plementary Tables 12–13 list the top 25 probesets in each direction).
Polimunol consistently upregulated CYP1B1 relative to GA (all 4
probesets on chip: adj p values 4.5e−11, 3.6e−9, 1.6e−8, 1.1e−7;
see Fig. 6a). Also, relative to GA, Polimunol upregulated genes involved
in inﬂammatory pathways, including IL1B, MMP9, CCL2, CCL5, and
CXCL1 (adj p values 1.2e−7, 2.0e−4, 2.7e−7, 0.01, and 4.3e−5,
respectively).
Using the DAVID platform, 137 pathways were enriched among top
probesets (obtained via ﬁltering both as described above and by FC as
described in Section 2) upregulated by Polimunol relative to GA. These
pathways include a variety of immune-related pathways expected to
be relevant to GA's MoA, including the cytokine–cytokine receptor in-
teraction pathway (adj p b 1.9e−5) that was also enriched among
probesets modulated by GA (see previous section), and positive regula-
tion of cytokine production (adjusted p b 0.004). These pathways also
include inﬂammation related pathways, such as inﬂammatory response
(adjusted p b 0.001), NOD-like receptor signaling (adjusted p b 0.02),
and response to lipopolysaccharide (adjusted p b 0.006). The top 25
pathways are listed in Supplementary Table 14, and the key pathways
illustrated in Fig. 6b. The speciﬁc genes in the response to lipopolysac-
charide pathway are depicted in Fig. 6c, and the genes in the
cytokine–cytokine receptor interaction pathway are depicted in
Supplementary Fig. 4.
3.2.2.1. Secreted proteins modulated by FOGA relative to GA. To evaluate
differences between GA and FOGA at the protein level, a custom panel
of 42 secreted cytokines and chemokines were measured from the su-
pernatant of THP-1 cells stimulated for 24 hwith GA, FOGA, ormannitol
Fig. 5. Anti-inﬂammatory gene IL1RN is signiﬁcantly upregulated by Copaxone (a); pathways enriched among top probesets modulated by Copaxone relative to mannitol control (b).
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levels were lowered by FOGA treatment relative to GA. FOGA treatment
signiﬁcantly increased the levels of 23 proteins (out of 39 having sufﬁ-
cient measurements for testing; Supplementary Table 15). These in-
clude IFNg, TNFa, MIP-1a (CCL3), IL-8 (CXCL8), and IL-10. Consistent
with the result observed at the mRNA expression level discussed
above, secreted levels of MMP-9, MCP-1 (CCL2), RANTES (CCL5),
Gro-a (CXCL1), and IL-1b were increased with FOGA treatment relative
to GA (Fig. 7; adjusted p values as shown).4. Discussion
T cells and antigen-presenting cells (APCs) are the two critical com-
ponents that together with GA (or the autoantigen) comprise the im-
munogenic triad responsible for aspects of the antigenic MoA of GA. A
comprehensive analysis of both cell types has been pursued, and
follow-up experiments further conﬁrmed the validity of ﬁndings, both
in terms of technological platform (genome-wide expression proﬁles
conﬁrmed by qRT-PCR), and biologically (protein secretion levels
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in a parallel, reciprocal-control experimental design. Gene-level and
pathway-level analyses identify known and novel modulatory effects
of GA associated with its therapeutic effect, and reveal functionally rel-
evant differences between GA and FOGA Polimunol that may shed light
on clinical effects in multiple sclerosis patients.
As one approach to modeling T-cell relevant effects, a mouse
splenocyte system was used, combined with a reciprocal experimental
design which enabled the study of 3 scenarios: switching from GA to
Polimunol, switching from Polimunol to GA, and comparing the impact
of consistent GA use with the impact of consistent Polimunol use. The
immunized mouse splenocyte system has been previously proven to
be informative in examining GA's mode of action, as well as in differen-
tiating between seemingly similar differently-manufactured GAs and
GA (Bakshi et al., 2013; Towﬁc et al., 2014) in GA immunization scenar-
ios, and the reciprocal experimental design used herein greatly expands
the sensitivity and speciﬁcity of the overall functional insights associat-
ed with unique attributes of GA and as compared with differentially
manufactured FOGAs.
More than two thirds of the probesets expressed in the spleen were
signiﬁcantly modulated by GA treatment, and the top modulated
probesets in either direction were enriched for many relevant path-
ways, including immune response and cytokine–cytokine receptor in-
teraction pathways. Key anti-inﬂammatory cytokine genes, such as
Il10 and Il4, and regulatory T cell markers, such as Foxp3 and Gpr83,
are upregulated by GA, while pro-inﬂammatory cytokine gene Il12a is
downregulated by GA treatment in this model system, consistent with
induction of a Th1 to Th2 shift. Thus, these studies help to illustrate
the complexity of GA's MoA, and provide validation of the experimental
system.
Several of these pathways were similar to those observed in an
earlier splenocyte study of similar design (Bakshi et al., 2013), despite
that fact that these studies were conducted using different microarray
platforms (Illumina versus Affymetrix), different pathway analysis plat-
forms (Ingenuity Pathway Analysis versus DAVID enrichment), and
different negative controls (medium versus mannitol). These include
upregulated lymphocyte activation and downregulated hematopoietic
cell lineage.
Downregulation of both Il18 and Il18r1 expression upon GA treat-
ment has been previously reported (Bakshi et al., 2013). In the current
study, in addition to these effects, a reciprocal effect was noted for
probesets of the IL-18 inhibitor, Il18bp, upregulated by GA treatment.
The fact that Polimunol consistentlymodulates Il18 to a signiﬁcantly dif-
ferent extent than GA, regardless of immunization agent, warrants fur-
ther investigation as it has potential implications for both safety and
efﬁcacy. IL-18 is important for T helper cell differentiation, and IL-18
levels are higher in serum from multiple sclerosis patients versus con-
trols, as well as acute versus stable multiple sclerosis (Nicoletti et al.,
2001). IL-18 also induces IFNg expression and has been implicated
in multiple sclerosis immunopathogenesis (Losy and Niezgoda, 2001).
IL-18 genetic variants have further been shown to affect multiple
sclerosis risk (Karakas Celik et al., 2014; Thompson and Humphries,
2007). Moreover, mice deﬁcient for IL-18 are resistant to EAE
(Shi et al., 2000).
A number of interferon-related genes are upregulated by Polimunol
relative to GA in this system, in both the microarray data and qRT-PCR
conﬁrmation. Fig. 4c shows illustrated pathways of IFN Type I produc-
tion (Trinchieri, 2010), with overlay indicating genes including RIG-I,
MDA5, and IRF7 upregulated by Polimunol versus GA. As indicated,
upregulation of these genes would be consistent with increased type I
interferon production.Fig. 6.Polimunol differs fromGA treatment at the gene expression level. (a) CYP1B1 is signiﬁcan
probesets differentially expressed between Polimunol andGA. (c) Volcano plot showing probese
upregulated by Polimunol relative to GA. The dashed line indicates signiﬁcance level of adjusteAt the pathway level, a variety of immune-related pathways are
enriched among the differentially-expressed probesets, including
“immune system process” and “response to virus,” and differential
expression is seen for multiple genes affecting interferon signaling
(e.g., leading to signiﬁcant enrichment of the RIG-I-like receptor signal-
ing pathway), together raising serious concerns for safety and efﬁcacy.
Chronic long-term changes in expression of key genes, regardless
of the magnitude of fold change, could impact pathways relevant to
multiple sclerosis.
APCs play a central role in the MoA of GA, by presenting GA to
T cells during priming at the periphery, by possibly also introducing
GA-speciﬁc T cells to auto-antigens in the brain (though such cross-
reactivity is not required for beneﬁt), and by changing cytokine
secretion proﬁle in response to GA. GA shifts monocytes to a type II,
anti-inﬂammatory state marked by increased production of anti-
inﬂammatory cytokines (e.g., IL-10) and decreased production of
pro-inﬂammatory cytokines (e.g., IL-12) (Weber et al., 2007).
Hundreds of genes are differentially expressed in humanmonocytes
following activation with Polimunol compared with activation with GA.
This stands in sharp contrast to the lack of differences between the three
different lots of GA tested in parallel, under blinding, in the same
experiment (Supplementary Table 16). The fact that the differentially-
expressed genes are enriched in key biological pathways such as
“immune response” supports the biological relevance of the observed
differences. Many of the pathways enriched among the differentially-
expressed genes are relevant to GA's MoA, such as cytokine-cytokine
receptor interactions, and relevant to potential safety concerns, such as
inﬂammatory response and response to lipopolysaccharide pathways.
The response to lipopolysaccharide pathway was also enriched
among genes differentially expressed by another purported generic,
Probioglat (Kolitz et al., 2015). Out of the 137 pathways enriched
among probesets upregulated by Polimunol relative to GA, 37 of these
pathways were also enriched in the prior comparison with Probioglat
(out of 64 total pathways seen for Probioglat). Of note, the introduction
of Probioglat in Mexicowas associated with a 3-fold increase in adverse
events and a 7-fold increase in relapses (Kolitz et al., 2015).
Protein-level measurements in THP-1 cells supported the gene-level
differences. Secretion of inﬂammation-related proteins (including
IL-1b, MCP-1, RANTES, Gro-a, and MMP-9) was higher with Polimunol
versus GA treatment, consistent with the microarray data described
above.
Synthon's Polimunol glatiramoid is marketed in Argentina (as of
May 2014) as a purported clinical equivalent to GA. Polimunol is be-
lieved to be the same product used in the only clinical trial conducted
to date with the objective of demonstrating equivalence in terms of
MRI imaging measurements (Cohen et al., 2014). Yet this clinical
study (GATE) despite its large sample size, raises important questions
regarding the reported clinical measures. For instance, given the sample
size of GATE (Copaxone= 357, Placebo= 84), the probability of show-
ing any level of annualized relapse rate (ARR) reduction (ie, clinical ef-
ﬁcacy) compared with placebo, of the reference, well-established drug
Copaxone, was high (N90%) based on results from multiple prior ran-
domized, placebo-controlled studies with Copaxone® conducted by
various sponsors over the last 2 decades. However, no effect in reducing
ARR was recorded for the Copaxone arm versus placebo in the GATE
study (an unlikely result expected to occur in only 10% of cases),
attesting to the lack of assay sensitivity (ie, ability to distinguish an ef-
fective drug from an ineffective one). Additionally, the rate of adverse
events leading to discontinuation was higher in the Synthon product
arm than in the Copaxone arm (12 vs 5), which may be underlied to a
certain extent by upregulation of pro-inﬂammatory pathways, a patterntly upregulated by Polimunol relative to GA. (b) Pathways signiﬁcantly enriched among top
ts driving the enrichment of the response to lipopolysaccharide pathway amongprobesets
d p value b 0.05.
Fig. 7. Polimunol differs fromGA treatment at the protein level. (a) Consistentwith gene level data, levels ofMMP-9,MCP-1 (CCL2), RANTES (CCL5), Gro-a (CXCL1), and IL-1bwere higher
with Polimunol versus GA treatment. (b) Levels of IFNg, TNFa, MIP1a (CCL3), IL-8 (CXCL8), and IL-10 were higher with Polimunol versus GA treatment.
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95T. Hasson et al. / Journal of Neuroimmunology 290 (2016) 84–95similar to that reported for the Probioglat FOGA (Kolitz et al., 2015). Our
ﬁndings demonstrate signiﬁcant differences betweenGA and Polimunol
at the mRNA, protein, and pathway levels.
4.1. Conclusions
Gene expression studies reported here add to the data around
GA MoA, presenting comprehensive data from a human monocyte
cell line in combination with a reciprocal-control mouse splenocyte
model. Both of these studies employ a whole-genome based approach,
looking across the entire expression array in an unbiased fashion, in
model systems capturing differing, relevant aspects of GA's effects. The
mouse splenocyte model used a novel reciprocal experimental design
that enabled themodeling of patients switching to and from a different-
ly manufactured glatiramoid, as well as comparing patients purely
treated with GA with those purely treated with a differently
manufactured glatiramoid. The resulting ﬁndings highlight the
complexity of GA's MoA, modulating thousands of genes in dozens of
different pathways. The biological impact is particularly sensitive to dif-
ferences in composition and manufacturing (Weinstein et al., 2015).
Signiﬁcant differences were identiﬁed between the gene expression
proﬁles modulated by Synthon's Polimunol and the proﬁles modulated
by GA, in both human monocytes and mouse splenocytes. These data
are in line with the signiﬁcant differences between GA and Polimunol
observed in multiple state-of-the-art physicochemical analyses
(Weinstein et al., 2015). How best to determine whether a differently
manufactured glatiramoid is as safe and effective as GA is the subject
of active research.
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